SCHEMBL31705095

SCHEMBL31705095

COc1cc(Cl)c(S(C)(=N)=O)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ ALDH1A1 P00352 7/20 0.44
▸ HPGD P15428 2/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA3 P07451 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA5A P35218 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA13 Q8N1Q1 1/20 0.44
▸ CISD1 Q9NZ45 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ CA5B Q9Y2D0 1/20 0.44
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ MRGPRX4 Q96LA9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8576478 0.88 KDM4E (0.52) KDM4ENPSR1ALDH1A1HPGDCA12
SCHEMBL10721874 0.84 KDM4E (0.52) KDM4ENPSR1ALDH1A1HPGDCA12
SCHEMBL28899597 0.83 CISD1 (0.66) KDM4ENPSR1CA12CA1CA2
SCHEMBL31704479 0.82 CA12 (0.64) ALDH1A1CA12CA1CA2CA3
SCHEMBL10725174 0.82 KDM4E (0.50) KDM4ENPSR1ALDH1A1HPGDCA12
SCHEMBL3387534 0.78 ALDH1A1 (0.56) KDM4ENPSR1ALDH1A1HPGDCA12
SCHEMBL6743024 0.77 LCK (0.58) KDM4ENPSR1ALDH1A1HPGDLCK
SCHEMBL10721823 0.76 LCK (0.59) KDM4ENPSR1ALDH1A1HPGDCA12
SCHEMBL11175056 0.76 KMT2A (0.71) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL7797968 0.76 KDM4E (0.65) KDM4ENPSR1ALDH1A1HPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215115-A1 COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES B&A ONCOMEDICAL (FR) 2025-10-16 — — WO disclosed
Send feedback